AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03628144
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care: Chemotherapy as already planned for each participant.
Trial: NCT03836833
Drug: ABC/3TC/LPV/r granules (30/15/40/10 mgs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day
Trial: NCT03836833
Drug: LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day
Trial: NCT00737568
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
Trial: NCT00737568
Drug: TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF placebo tablet administered orally once daily
Trial: NCT00737568
Drug: FTC/TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC/TDF placebo tablet administered orally once daily
Trial: NCT00656188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00704483
Drug: SBR759
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
Trial: NCT00704483
Drug: SBR759
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g tid
Trial: NCT00380991
Drug: lactoserum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01743235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Trial: NCT01743235
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Trial: NCT02213848
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
Trial: NCT02966964
Drug: DWPUR001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02966964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02626234
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02626234
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02472418
Drug: DFN-15 Dose B (treatment B)
RxNorm normalized name: sennoside B 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-15 Dose B administered
Trial: NCT03117790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
Trial: NCT00835640
Drug: ALLEGRA® 180 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 180 mg
Trial: NCT03193814
Drug: Chemotherapy + Apatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
Trial: NCT00274898
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04347473
Drug: Ilumya Injectable Product
RxNorm normalized name: Ilumya Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-23 injection
Trial: NCT02975011
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
Trial: NCT02241811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel without 3% Sodium Pentaborate Pentahydrate
Trial: NCT00364572
Drug: placebo (control procedure)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections of epidural saline 2 weeks apart
Trial: NCT00664313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given daily for 112 doses (16 weeks)
Trial: NCT01725230
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20-mg tablet
Trial: NCT01725230
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40-mg tablet
Trial: NCT00940095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of placebo-matching clazosentan
Trial: NCT02664051
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg 4x2 daily mannitol
Trial: NCT00066469
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
Trial: NCT04092907
Drug: HBM9036 0.25% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution
Trial: NCT04092907
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution
Trial: NCT00864669
Drug: CLUCOPHAGE® XR 500 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
Trial: NCT01955434
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00394901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
Trial: NCT01467115
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
Trial: NCT01467115
Drug: Erythropoetin
RxNorm normalized name: Erythropoetin zeta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous or intravenous
Trial: NCT01467115
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
Trial: NCT02076399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet PO bid (morning and evening) over the course of 24 weeks
Trial: NCT01480713
Drug: Isentress® (Raltegravir, 400 mg every 12 hours)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
Trial: NCT01480713
Drug: Isentress® (Raltegravir, 400 every 12 hours)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
Trial: NCT01840774
Drug: Low-dose pain medication (Ketalar) and saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02720601
Drug: Irinotecan & Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
Trial: NCT03080545
Drug: Enstilar 0.005%-0.064% Topical Foam
RxNorm normalized name: Enstilar 0.005%-0.064% Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical foam
Trial: NCT02279719
Drug: BBI608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
Trial: NCT02279719
Drug: BBI503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
Trial: NCT00002955
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002955
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03817463
Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipeptidyl peptidase-4 (DPP-4) inhibitor
Trial: NCT01559259
Drug: Ibuprofen/acetaminophen
RxNorm normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
Trial: NCT01559259
Drug: Ibuprofen/acetaminophen
RxNorm normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
Trial: NCT01559259
Drug: Ibuprofen/acetaminophen
RxNorm normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
Trial: NCT01559259
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two caplets of ibuprofen 200 mg
Trial: NCT01559259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two caplets of placebo
Trial: NCT00355537
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustanon- intramuscular testosterone 200mg every 2 weeks
Trial: NCT00355537
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injection intramuscular every 2 weeks
Trial: NCT01159171
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
Trial: NCT00896363
Drug: GSK163090 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developed for the treatment of Major Depressive Disorder
Trial: NCT00896363
Drug: GSK163090 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developed for the treatment of Major Depressive Disorder
Trial: NCT00896363
Drug: GSK163090 3 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developed for the treatment of Major Depressive Disorder
Trial: NCT00121524
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine 1 mg is given iv. every 3 min during CPR
Trial: NCT02759107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03504982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
Trial: NCT00062023
Drug: Acetylsalicylic acid (Aspirin)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive oral aspirin once daily for 12 months.
Trial: NCT00062023
Drug: Sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive oral sulindac twice daily for 12 months.
Trial: NCT00395291
Drug: MK-0677
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
Trial: NCT00395291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03691818
Drug: X0002 Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
Trial: NCT03691818
Drug: Ibuprofen Tablet
RxNorm normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen Tab 400mg, tid.
Trial: NCT03691818
Drug: Ibuprofen Placebo Tab
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen Placebo Tab 400mg, tid.
Trial: NCT03691818
Drug: X0002 Placebo Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
Trial: NCT00989521
Drug: PUR003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR003 for inhalation
Trial: NCT00989521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline for inhalation
Trial: NCT00785421
Drug: only chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: observation, no treatment with LMWH
Trial: NCT00074529
Drug: MK0677
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01242306
Drug: intracoronary infusion of acetylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
Trial: NCT03638908
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03452917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 patients will 2 ml of normal saline
Trial: NCT02567370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00657839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT03860012
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
Trial: NCT02200328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
Trial: NCT02966093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
Trial: NCT02976766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo three times a day for 10 days.
Trial: NCT00191724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (IV), one infusion, over 12 hours
Trial: NCT00873535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
Trial: NCT01611363
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01611363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02958436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01529515
Drug: PP3M 175 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Trial: NCT01529515
Drug: PP3M 263 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Trial: NCT01135186
Drug: sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sapropterin dihydrochloride: 10mg/kg/day
Trial: NCT01529515
Drug: PP3M 350 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Trial: NCT01529515
Drug: PP3M 525 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Trial: NCT01529515
Drug: Placebo (20% Intralipid emulsion)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Trial: NCT03920293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
Trial: NCT00544453
Drug: [123I] MNI-308
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of \[123I\] MNI-308 and SPECT scanning
Trial: NCT03100916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT02568098
Drug: IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
Trial: NCT02568098
Drug: DHA-PQP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 6: DHA-PQP
Trial: NCT01338350
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation, suspension
Trial: NCT01338350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation, solution
Trial: NCT02845908
Drug: POF
RxNorm normalized name: Ta-Poff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
Trial: NCT02845908
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin plus Leucovorin plus 5-FU
Trial: NCT02845908
Drug: FOLFOX plus PAC(ip)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX plus intraperitoneally PAC
Trial: NCT04170530
Drug: mFOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan\* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Trial: NCT02022215
Drug: ME1111 Solution, Low strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME1111 Solution, Low strength, applied once daily for 48 weeks
Trial: NCT02022215
Drug: ME1111 Solution, High strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME1111 Solution, High strength, applied once daily for 48 weeks